Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price10,764.00 INR
Ethical score0.0/100
RatingAVOID
Our investment reviews on this name
2026-08-21Read Markdown10,795.00-0.3% to today ✓
2026-07-02Read Distribution10,795.00-0.3% to today ✓
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
UltraTech Cement holds its Markdown at $10,764.00. Consolidating, no directional conviction, held for 1 days.
As held on the ledger · 2026-09-17
Phase
Markdown · caution
Quantitative state
Consolidating, no directional conviction, held for 1 days
Price at the screen
$10,764.00
Valuation
0.00 trailing · 0.00 forward price to earnings
Values screen
FAIL· score 0.0
The Workings
Five Screens, Shown in Full
Does not pass. Business activity: leveraged / inverse / derivative instrument (gharar)
Test
Figure
Limit
What it means
Status
Business activity
Excluded
Core business clean
Passes business activity screen
Fail
Debt load
16.80%
Below 33%
Interest-bearing debt is just 16.8% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.61%
Below 33%
Cash held in interest-bearing accounts and securities is 0.6% of assets, under the one-third limit.
Pass
Receivables
4.52%
Below 49%
Money owed to the company is 4.5% of assets, under the 49% limit.
Pass
Revenue purity
0.30%
Below 5%
Only 0.3% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
UltraTech Cement does not clear the screen at the business-activity stage. It operates in an area the screen excludes: Passes business activity screen, so the financial ratios are not the deciding factor here.
Read as at 2026-10-04. It updates when the underlying figures move, and past reads are kept below.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads AVOID
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-17 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Why it gives us pause
On our numbers, the price already runs ahead of the business.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ULTRACEMCO.NS trades on NSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-02Markdown$10,764.00+0.0%Entry 10
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (39 analysts) rates it none, with a mean price target of $13721.
2026-09-24Markdown$10,764.00-0.3%Entry 9
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (39 analysts) rates it none, with a mean price target of $13721.
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (39 analysts) rates it none, with a mean price target of $13721.
2026-07-20Distribution$10,795.00+0.0%Entry 7
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (39 analysts) rates it none, with a mean price target of $13721. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-19Distribution$10,795.00+0.0%Entry 6
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (39 analysts) rates it none, with a mean price target of $13721. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-18Distribution$10,795.00+0.0%Entry 5
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (39 analysts) rates it none, with a mean price target of $13721. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-17Distribution$10,795.00+0.0%Entry 4
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (39 analysts) rates it none, with a mean price target of $13721. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-16Distribution$10,795.00+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (39 analysts) rates it none, with a mean price target of $13721. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-03Distribution$10,795.00+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Distribution$10,795.00Entry 1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.